<SEC-DOCUMENT>0001214659-26-003867.txt : 20260327
<SEC-HEADER>0001214659-26-003867.hdr.sgml : 20260327
<ACCEPTANCE-DATETIME>20260327061301
ACCESSION NUMBER:		0001214659-26-003867
CONFORMED SUBMISSION TYPE:	SCHEDULE 13D/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20260327
DATE AS OF CHANGE:		20260327

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IceCure Medical Ltd.
		CENTRAL INDEX KEY:			0001584371
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-92815
		FILM NUMBER:		26800786

	BUSINESS ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		7 HA'ESHEL ST., POB 3163
		CITY:			CAESAREA
		PROVINCE COUNTRY:   	L3
		ZIP:			38900
		BUSINESS PHONE:		972-4-6230333

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		7 HA'ESHEL ST., POB 3163
		CITY:			CAESAREA
		PROVINCE COUNTRY:   	L3
		ZIP:			38900

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Haixiang Li
		CENTRAL INDEX KEY:			0002067600
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D/A

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		STE 7013, 70F 2 INTERNATIONAL FIN CENTRE
		STREET 2:		8 FINANCE STREET
		CITY:			CENTRAL, HONG KONG
		PROVINCE COUNTRY:   	K3
		ZIP:			NULL
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13D/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13D" xmlns:com="http://www.sec.gov/edgar/common">
  <schemaVersion>X0202</schemaVersion>
<headerData>
    <submissionType>SCHEDULE 13D/A</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: Haixiang Li -->
          <cik>0002067600</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>


    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <amendmentNo>1</amendmentNo>
      <securitiesClassTitle>Ordinary Shares, no par value</securitiesClassTitle>
      <dateOfEvent>03/17/2026</dateOfEvent>
      <previouslyFiledFlag>false</previouslyFiledFlag>
      <issuerInfo>
        <issuerCIK>0001584371</issuerCIK>
        <issuerCusips>
          <issuerCusipNumber>M53071136</issuerCusipNumber>
        </issuerCusips>
        <issuerName>ICECURE MEDICAL LTD.</issuerName>
        <address>
          <com:street1>7 Ha Eshel Street</com:street1>
          <com:street2>P.O. Box 3163</com:street2>
          <com:city>Caesarea</com:city>
          <com:stateOrCountry>L3</com:stateOrCountry>
          <com:zipCode>3079504</com:zipCode>
        </address>
      </issuerInfo>
      <authorizedPersons>
        <notificationInfo>
          <personName>Li Haixiang</personName>
          <personPhoneNum>852 2385-8822</personPhoneNum>
          <personAddress>
            <com:street1>Ste 7013, 70F Two IFC</com:street1>
            <com:street2>8 Finance St</com:street2>
            <com:city>Hong Kong</com:city>
            <com:stateOrCountry>K3</com:stateOrCountry>
            <com:zipCode>518000</com:zipCode>
          </personAddress>
        </notificationInfo>
      </authorizedPersons>
    </coverPageHeader>
    <reportingPersons>
      <reportingPersonInfo>
        <reportingPersonCIK>0002067600</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>Mr. Li Haixiang</reportingPersonName>
        <fundType>OO</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>K3</citizenshipOrOrganization>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>35846597.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>35846597.00</sharedDispositivePower>
        <aggregateAmountOwned>35846597.00</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>45.8</percentOfClass>
        <typeOfReportingPerson>IN</typeOfReportingPerson>
        <commentContent>See Item 5 for beneficial ownership information of the Reporting Person. The percentage above is based on 73,122,293 Ordinary Shares of the Issuer that were outstanding as of December 31, 2025, based on information contained in the annual report on Form 20-F for the fiscal year ended December 31, 2025, filed by the Issuer on March 17, 2026.</commentContent>
      </reportingPersonInfo>
      <reportingPersonInfo>
        <reportingPersonCIK>0001912513</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>Epoch Partner Investments Limited</reportingPersonName>
        <fundType>OO</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>D8</citizenshipOrOrganization>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>35846597.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>35846597.00</sharedDispositivePower>
        <aggregateAmountOwned>35846597.00</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>45.8</percentOfClass>
        <typeOfReportingPerson>CO</typeOfReportingPerson>
        <commentContent>See Item 5 for beneficial ownership information of the Reporting Person. The percentage above is based on 73,122,293 Ordinary Shares of the Issuer that were outstanding as of December 31, 2025, based on information contained in the annual report on Form 20-F for the fiscal year ended December 31, 2025, filed by the Issuer on March 17, 2026.</commentContent>
      </reportingPersonInfo>
    </reportingPersons>
    <items1To7>
      <item1>
        <securityTitle>Ordinary Shares, no par value</securityTitle>
        <issuerName>ICECURE MEDICAL LTD.</issuerName>
        <issuerPrincipalAddress>
          <com:street1>7 Ha Eshel Street</com:street1>
          <com:street2>P.O. Box 3163</com:street2>
          <com:city>Caesarea</com:city>
          <com:stateOrCountry>L3</com:stateOrCountry>
          <com:zipCode>3079504</com:zipCode>
        </issuerPrincipalAddress>
        <commentText>This Amendment No. 1 to Schedule 13D (this "Schedule 13D/A"), which amends and supplements the Schedule 13D initially filed with the Securities and Exchange Commission (the "SEC") on May 14, 2025 (the "Schedule 13D"), by Epoch Partner Investments Limited ("Epoch") and Mr. Li Haixiang (collectively, the "Reporting Persons"), relates to the ordinary shares, no par value per share (the "Ordinary Shares"), of IceCure Medical Ltd., an Israeli company (the "Issuer"). This Schedule 13D/A is being filed to reflect that Mr. Li Haixiang resigned as a member of the Issuer's board of directors on March 17, 2026.</commentText>
      </item1>
      <item2>
        <filingPersonName>Epoch Partner Investments Limited ("Epoch") and Mr. Li Haixiang</filingPersonName>
        <principalBusinessAddress>The principal business and principal office address of the Reporting Persons is: Epoch Partner Investments Limited Suite 7013, 2 International Finance Centre, 70/F 8 Finance Street Central, Hong Kong.</principalBusinessAddress>
        <principalJob>Mr. Li Haixiang, the sole director of Epoch, is a former director of the Issuer and resigned from the Issuer's board of directors on March 17, 2026.</principalJob>
        <hasBeenConvicted>Neither of the Reporting Persons have, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).</hasBeenConvicted>
        <convictionDescription>Neither of the Reporting Persons have, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction as a result of which the Reporting Persons were or are subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.</convictionDescription>
        <citizenship>Epoch's place of organization is the British Virgin Islands. Mr. Li Haixiang is a citizen and resident of Hong Kong Special Administrative Region of the People's Republic of China and also a citizen of Cyprus.</citizenship>
      </item2>
      <item3>
        <fundsSource>This item is not being amended by this Schedule 13D/A.</fundsSource>
      </item3>
      <item4>
        <transactionPurpose>This item is not being amended by this Schedule 13D/A.</transactionPurpose>
      </item4>
      <item5>
        <percentageOfClassSecurities>"Item 5. Interest in Securities of the Issuer" of the Schedule 13D is hereby amended and restated as follows:

The aggregate percentage of Ordinary Shares reported owned by the Reporting Persons is based upon 73,122,293 Ordinary Shares outstanding as of December 31, 2025, as reported by the Issuer on March 17, 2026. The Reporting Persons are deemed to beneficially own an aggregate of 30,846,597 Ordinary Shares, representing approximately 45.8% of the outstanding Ordinary Shares.</percentageOfClassSecurities>
        <numberOfShares>"Item 5. Interest in Securities of the Issuer" of the Schedule 13D is hereby amended and restated as follows:

The Reporting Persons hold shared voting and dispositive power over all of the Ordinary Shares that the Reporting Persons beneficially owned as of December 31, 2025.

Epoch directly holds the Ordinary Shares reported herein. Mr. Li Haixiang's beneficial ownership of the Issuer's securities arises solely from his position as the sole director of Epoch.</numberOfShares>
        <transactionDesc>The Reporting Persons have not effected any transactions in the Ordinary Shares of the Issuer in the past 60 days.</transactionDesc>
        <listOfShareholders>No other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities beneficially owned by the Reporting Persons.</listOfShareholders>
        <date5PercentOwnership>Not applicable.</date5PercentOwnership>
      </item5>
      <item6>
        <contractDescription>This item is not being amended by this Schedule 13D/A.</contractDescription>
      </item6>
      <item7>
        <filedExhibits>This item is not being amended by this Schedule 13D/A.</filedExhibits>
      </item7>
    </items1To7>
    <signatureInfo>
      <signaturePerson>
        <signatureReportingPerson>Mr. Li Haixiang</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ Li Haixiang</signature>
          <title>Li Haixiang</title>
          <date>03/27/2026</date>
        </signatureDetails>
      </signaturePerson>
      <signaturePerson>
        <signatureReportingPerson>Epoch Partner Investments Limited</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ Li Haixiang on behalf of Epoch Partner Investments Limited</signature>
          <title>Li Haixiang, Director</title>
          <date>03/27/2026</date>
        </signatureDetails>
      </signaturePerson>
    </signatureInfo>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
